BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 22505410)

  • 1. Structural analysis of Pneumocystis carinii dihydrofolate reductase complexed with NADPH and 2,4-diamino-6-[2-(5-carboxypent-1-yn-1-yl)-5-methoxybenzyl]-5-methylpyrido[2,3-d]pyrimidine.
    Cody V; Pace J; Stewart E
    Acta Crystallogr Sect F Struct Biol Cryst Commun; 2012 Apr; 68(Pt 4):418-23. PubMed ID: 22505410
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structural analysis of Pneumocystis carinii and human DHFR complexes with NADPH and a series of five potent 6-[5'-(ω-carboxyalkoxy)benzyl]pyrido[2,3-d]pyrimidine derivatives.
    Cody V; Pace J
    Acta Crystallogr D Biol Crystallogr; 2011 Jan; 67(Pt 1):1-7. PubMed ID: 21206056
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New insights into DHFR interactions: analysis of Pneumocystis carinii and mouse DHFR complexes with NADPH and two highly potent 5-(omega-carboxy(alkyloxy) trimethoprim derivatives reveals conformational correlations with activity and novel parallel ring stacking interactions.
    Cody V; Pace J; Chisum K; Rosowsky A
    Proteins; 2006 Dec; 65(4):959-69. PubMed ID: 17019704
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structure-activity correlations for three pyrido[2,3-d]pyrimidine antifolates binding to human and Pneumocystis carinii dihydrofolate reductase.
    Cody V; Pace J; Namjoshi OA; Gangjee A
    Acta Crystallogr F Struct Biol Commun; 2015 Jun; 71(Pt 6):799-803. PubMed ID: 26057816
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of quinazoline and pyrido[2,3-d]pyrimidine N9-C10 reversed-bridge antifolates in complex with NADP+ and Pneumocystis carinii dihydrofolate reductase.
    Cody V; Galitsky N; Luft JR; Pangborn W; Queener SF; Gangjee A
    Acta Crystallogr D Biol Crystallogr; 2002 Sep; 58(Pt 9):1393-9. PubMed ID: 12198294
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Selective Pneumocystis carinii dihydrofolate reductase inhibitors: design, synthesis, and biological evaluation of new 2,4-diamino-5-substituted-furo[2,3-d]pyrimidines.
    Gangjee A; Guo X; Queener SF; Cody V; Galitsky N; Luft JR; Pangborn W
    J Med Chem; 1998 Apr; 41(8):1263-71. PubMed ID: 9548816
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis and biological evaluation of 2,4-diamino-6-(arylaminomethyl)pyrido[2,3-d]pyrimidines as inhibitors of Pneumocystis carinii and Toxoplasma gondii dihydrofolate reductase and as antiopportunistic infection and antitumor agents.
    Gangjee A; Adair OO; Queener SF
    J Med Chem; 2003 Nov; 46(23):5074-82. PubMed ID: 14584957
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structure-based enzyme inhibitor design: modeling studies and crystal structure analysis of Pneumocystis carinii dihydrofolate reductase ternary complex with PT653 and NADPH.
    Cody V; Galitsky N; Luft JR; Pangborn W; Rosowsky A; Queener SF
    Acta Crystallogr D Biol Crystallogr; 2002 Jun; 58(Pt 6 Pt 2):946-54. PubMed ID: 12037296
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structural studies on bioactive compounds. 30. Crystal structure and molecular modeling studies on the Pneumocystis carinii dihydrofolate reductase cofactor complex with TAB, a highly selective antifolate.
    Cody V; Chan D; Galitsky N; Rak D; Luft JR; Pangborn W; Queener SF; Laughton CA; Stevens MF
    Biochemistry; 2000 Apr; 39(13):3556-64. PubMed ID: 10736154
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design, synthesis, and antifolate activity of new analogues of piritrexim and other diaminopyrimidine dihydrofolate reductase inhibitors with omega-carboxyalkoxy or omega-carboxy-1-alkynyl substitution in the side chain.
    Chan DC; Fu H; Forsch RA; Queener SF; Rosowsky A
    J Med Chem; 2005 Jun; 48(13):4420-31. PubMed ID: 15974594
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis and biological evaluation of nonclassical 2,4-diamino-5-methylpyrido[2,3-d]pyrimidines with novel side chain substituents as potential inhibitors of dihydrofolate reductases.
    Gangjee A; Vasudevan A; Queener SF
    J Med Chem; 1997 Feb; 40(4):479-85. PubMed ID: 9046338
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ligand-induced conformational changes in the crystal structures of Pneumocystis carinii dihydrofolate reductase complexes with folate and NADP+.
    Cody V; Galitsky N; Rak D; Luft JR; Pangborn W; Queener SF
    Biochemistry; 1999 Apr; 38(14):4303-12. PubMed ID: 10194348
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 6-Substituted 2,4-diaminopyrido[3,2-d]pyrimidine analogues of piritrexim as inhibitors of dihydrofolate reductase from rat liver, Pneumocystis carinii, and Toxoplasma gondii and as antitumor agents.
    Gangjee A; Zhu Y; Queener SF
    J Med Chem; 1998 Nov; 41(23):4533-41. PubMed ID: 9804692
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New 2,4-diamino-5-(2',5'-substituted benzyl)pyrimidines as potential drugs against opportunistic infections of AIDS and other immune disorders. Synthesis and species-dependent antifolate activity.
    Rosowsky A; Forsch RA; Sibley CH; Inderlied CB; Queener SF
    J Med Chem; 2004 Mar; 47(6):1475-86. PubMed ID: 14998335
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of Pneumocystis carinii, Toxoplasma gondii, and Mycobacterium avium dihydrofolate reductases by 2,4-diamino-5-[2-methoxy-5-(omega-carboxyalkyloxy)benzyl]pyrimidines: marked improvement in potency relative to trimethoprim and species selectivity relative to piritrexim.
    Rosowsky A; Forsch RA; Queener SF
    J Med Chem; 2002 Jan; 45(1):233-41. PubMed ID: 11754594
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Kinetic and structural analysis for potent antifolate inhibition of Pneumocystis jirovecii, Pneumocystis carinii, and human dihydrofolate reductases and their active-site variants.
    Cody V; Pace J; Queener SF; Adair OO; Gangjee A
    Antimicrob Agents Chemother; 2013 Jun; 57(6):2669-77. PubMed ID: 23545530
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Correlations of inhibitor kinetics for Pneumocystis jirovecii and human dihydrofolate reductase with structural data for human active site mutant enzyme complexes.
    Cody V; Pace J; Makin J; Piraino J; Queener SF; Rosowsky A
    Biochemistry; 2009 Mar; 48(8):1702-11. PubMed ID: 19196009
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structure determination of tetrahydroquinazoline antifolates in complex with human and Pneumocystis carinii dihydrofolate reductase: correlations between enzyme selectivity and stereochemistry.
    Cody V; Luft JR; Pangborn W; Gangjee A; Queener SF
    Acta Crystallogr D Biol Crystallogr; 2004 Apr; 60(Pt 4):646-55. PubMed ID: 15039552
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pneumocystis carinii and Toxoplasma gondii dihydrofolate reductase inhibitors and antitumor agents: synthesis and biological activities of 2,4-diamino-5-methyl-6-[(monosubstituted anilino)methyl] pyrido[2,3-d]pyrimidines.
    Gangjee A; Adair O; Queener SF
    J Med Chem; 1999 Jul; 42(13):2447-55. PubMed ID: 10395486
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structural analysis of a holoenzyme complex of mouse dihydrofolate reductase with NADPH and a ternary complex with the potent and selective inhibitor 2,4-diamino-6-(2'-hydroxydibenz[b,f]azepin-5-yl)methylpteridine.
    Cody V; Pace J; Rosowsky A
    Acta Crystallogr D Biol Crystallogr; 2008 Sep; 64(Pt 9):977-84. PubMed ID: 18703847
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.